Recently, NHE9 has been shown to induce CRT resistance in ESCC by upregulating the Src/Akt/β-catenin pathway and Bcl-2 expression suggesting its potential as an effective predictor of CRT response and may be useful in the development of targeted therapies for CRT-resistant ESCC [22]. Here, SLC9A9 is linked to esophageal squamous cell carcinoma.